Clayton Foundation For Research

A research project at Baylor College of Medicine in gene and protein therapy focuses on inappropriate cell division and cell death within the human body. Much of the work is devoted to intraocular angiogenesis, with particular attention to: (1) the signals that control this process, (2) the development of animal models of human ocular disease, and (3) development of potential therapies. New targets have been identified and potential therapeutic agents are being developed and tested for the treatment of wet AMD, Diabetic Retinopathy, and Retinopathy of Prematurity.

The conduct of a longstanding research program at the University of Texas M. D. Anderson Cancer Center(which program moved to Texas A&M Institute of Biosciences and and Technology during the year) , the purpose of which is to design and develop novel targeted therapeutic agents that target a powerful human toxin to specifically destroy cancer cells for the treatment of numerous cancer targets and other disease indications. A number of collaborations have been undertaken with researchers at various institutions (e.g., University of California San Diego). Patent applications have been filed by Research Development Foundation (RDF), a tax exempt supporting organization of the Foundation (see schedule R, Part III), on more than twenty discoveries, and a number of patents have been issued. Licensing efforts have been ongoing and have resulted in several licenses.

Vaccines, Diagnostics and Therapeutics for the Ehrlichioses at The Univerity of Texas Medical Branch at Galveston

Development of Biorepository and Novel Therapeutic Strategies for Hepatocellular Carcinoma at the University of Texas Health Science Center at San Antonio

Early Detection and Treatment of Glaucoma Baylor College of Medicine Houston

Identification of Host-based Antiviral Targets at the University of Texas Southwestern Medical Center Dallas

The Use of Light for Cardiological, Surgical, and Related Purposes at the University of Texas Health Science Center at San Antonio

Antibody Discovery and Optimization Using the Eclonal Technology at The University of Texas at Austin

Electroceutical Sciences and Medicine at Dell Medical School at the University of Texas

Developing Drug Delivery Systems for Testing Solid Tumors at Dell Medical School at the University of Texas

Discovering New Mechanisms and Therapeutics for Brain Injury at the University of Texas Southwestern Medical Center Dallas

Development of Artificial Neurotransmitter Systems at the University of Texas at Austin

Optimization and Charactorization of AAV for Gene Therapy at Dell Medical School at The University of Texas

Grants